We reported 14 leukemia patients transplanted with allogeneic peripheral blood stem cells (Allo-PBSCT) of HLA identical sibling, AML 5, ALL 4, CML 5. There were 12 patients in their early stage of leukemia, 2 in late stage. They were 32 (25–42) years old, 10 male and 4 female. After conditioned with CTX and fTBI, G/GM-CSF mobilized donor’s peripheral blood mononuclear cells (MNC) 4.80 (2.46–8.43)×108/kg and CD34+ cells 3.96 (1.01–10.08)x106/kg were infused respectively. CSA and MTX used as GVHD prophylaxis. After Allo-PBSCT, WBC rose to 1.0×109/L on day+17 (+12−+26) and platelet rose to 50×109/L on day +27 (+19−+35) respectively. The blood products support, the antibiotics used, and total environment protection duration decreased. Acute GVHD presented in 7 patients (50.0%). Four patients died in acute GVHD and infection on days of +73, +41 +57 and +49. The disease free survival days after Allo-PBSCT in the 10 patients was +137 (+91–+240) days. It is suggested that Allo-PBSCT probably has some advantage than that of Allo-BMT.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Kessinger A, Smith DM, Standjord SE, et al. Allogeneic transplantation of blood-derived, T cell-depleted hemopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia. Bone Marrow Transplant 1989; 4:643.
Korbling M, Huh YO, Durett A, et al. Allogeneic blood stem cell transplantation: Peripheralization and yield of donor-derived primitive haematopoietic progenitor cells (CD34+ Thy-ldim) and lymphoid subsets, and possible predictors of engraftment and Graft-Versus-Host Disease. Blood 1995; 86: 2842.
Fliedner TM. Blood stem cell transplantation: From preclinical to clinical models. Stem Cells 1995; 13: (Suppl 3) 1.
Richman CM, Weimer RS, Yankee RS. Increase in circulating stem cells following chemotherapy in man. Blood 1967; 47: 1034.
Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral-blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339:640.
Gratwohl A, Hermans J, Baidomero H. Haematopoietic precursor cell transplants in Europe: Activity in 1994. Report from the European Group for blood and marrow transplantation (EBMT). Bone marrow Transplant 1996; 17:137.
Goldman J. Peripheral blood stem cells for allografting. Blood 1995; 85:1413.
Azevedo WM, Aranha FJP, Gouvea JV, et al. Allogeneic transplantation with blood stem cells mobilized by rhG-CSF for hematological malignancies. Bone Marrow Transplant 1995; 16:61.
Knapp W, Strobl H, Scheinecker C, et al. Molecular characterization of CD34 human hematopoietic progenitor cells. Ann Hematol 1995; 70:281.
Weaver CH, Longin K, Buckner CD, et al. Lymphocyte content in peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony stimulating factor. bone Marrow Transplant 1994; 13:411.
Atkinson K, Farrell C, Champman G, et al. Female marrow donors increase the risk of acute graft-versus-host disease: effect of donor age and parity and analysis of cell subpopulations in the donor marrow inoculum. Br J Hematol 1986; 63:231.
Majolino I, Saglio G. Scime R, et al. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Bone Marrow Transplant 1996; 17:555.
Auquier P, Macquart-Moulin G, Moatti JP, et al. Cjomparison of anxiety, pain and discomfort in two procedures of hematopoietic stem cell collection: leukacytapheresis and bone marrow harvest. Bone Marrow Transplant 1995; 16:541.
Murphy WJ, Retbikds CW, Tiberghien P, et al. Natural killer cells and bone marrow transplantation. J Natl Cancer Inst 1993; 85:1475.
About this article
Cite this article
Cao, L., Hu, L., Chen, H. et al. Allogeneic peripheral blood stem cell transplantation in the treatment of leukemia. Chin J Cancer Res 9, 142–145 (1997). https://doi.org/10.1007/BF02974682